CN101229307A - 一种戒毒口服中药制剂及其制备工艺 - Google Patents
一种戒毒口服中药制剂及其制备工艺 Download PDFInfo
- Publication number
- CN101229307A CN101229307A CNA2008100174135A CN200810017413A CN101229307A CN 101229307 A CN101229307 A CN 101229307A CN A2008100174135 A CNA2008100174135 A CN A2008100174135A CN 200810017413 A CN200810017413 A CN 200810017413A CN 101229307 A CN101229307 A CN 101229307A
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- ginseng
- lofexidine
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title abstract description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 78
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 78
- 235000008434 ginseng Nutrition 0.000 claims abstract description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims abstract description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012567 medical material Substances 0.000 claims abstract description 9
- 241000208340 Araliaceae Species 0.000 claims description 77
- 210000000582 semen Anatomy 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000218176 Corydalis Species 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 240000000559 Albizia odoratissima Species 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 57
- 238000001784 detoxification Methods 0.000 abstract description 12
- 206010012335 Dependence Diseases 0.000 abstract description 7
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 abstract 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 244000044980 Fumaria officinalis Species 0.000 abstract 1
- 235000006961 Fumaria officinalis Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000208278 Hyoscyamus Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241001674034 Stephanotis Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 229940068560 greater celandine Drugs 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 65
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 54
- 229940079593 drug Drugs 0.000 description 38
- 239000008280 blood Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 14
- 208000019901 Anxiety disease Diseases 0.000 description 13
- 230000036506 anxiety Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 230000001550 time effect Effects 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 206010068887 Tobacco poisoning Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 8
- 229960005209 lofexidine Drugs 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940127240 opiate Drugs 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 241000220433 Albizia Species 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 239000008896 Opium Substances 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960001027 opium Drugs 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 206010013663 drug dependence Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
用药时间 | 戒断症状减分率(%) | |
延参组(n=311) | 洛非西定组(n=104) | |
D1D2D3D4D5D6D7D8D9D10 | 23.21±12.6044.86±15.0062.74±16.1074.00±14.0281.37±12.2886.09±11.4189.57±10.5392.22±10.1494.16±9.8895.63±9.74 | 20.76±10.3239.83±14.7356.15±15.2767.51±13.1577.10±11.4182.98±9.7587.71±7.7490.60±6.6392.90±6.0795.10±5.07 |
重复测量资料混合效应线性模型 | 组间差异 F=67.12 P<0.0001时间效应 F=1635.43 P<0.0001 |
用药时间 | 延参组 | 洛非西定组 | ||
n | 戒断症状减分率(%) | n | 戒断症状减分率(%) | |
D0D1D2D3D4 | 297297297297297 | 23.31±12.2745.19±14.3563.35±15.0674.68±12.3182.15±9.83 | 9999999999 | 20.37±9.8039.48±14.1956.12±15.3867.49±13.2677.27±11.49 |
D5D6D7D8D9D10 | 296295294294294294 | 87.07±8.0890.62±6.2393.29±5.0495.27±4.0196.79±3.2023.31±12.27 | 999999999999 | 83.12±9.8587.76±7.7090.72±6.4693.01±5.7795.29±4.5420.37±9.80 |
重复测量资料混合效应线性模型 | 组间差异时间效应 | F=146.21 P<0.0001F=2183.31 P<0.0001 |
用药时间 | 戒断症状总分 | |
延参组(n=311) | 洛非西定组(n=104) | |
D0D1D2D3D4D5D6D7D8D9D10 | 108.50±13.9683.02±16.2059.57±16.9440.14±17.0827.85±14.1419.86±12.0714.75±10.9011.05±9.888.19±9.346.12±9.004.50±8.76 | 107.80±15.0885.28±15.5164.74±17.0246.97±16.3734.59±13.1924.33±11.4317.99±9.4612.93±7.169.87±5.887.42±5.275.04±4.20 |
重复测量资料混合效应线性模型 | 组间差异 F=8.71 P=0.0033时间效应 F=1212.66 P<0.0001组间-时间交互作用 F=3.17 P=0.0006 |
用药时间 | 延参组 | 洛非西定组 | ||
n | 戒断症状总分 | n | 戒断症状总分 | |
D0D1D2D3D4D5D6D7D8D9D10 | 297297297297297296295294294294294 | 108.73±13.9383.15±16.1859.45±16.7339.73±16.6027.33±13.0719.21±10.4013.92±8.4810.13±6.637.25±5.295.13±4.223.45±3.22 | 9999999999999999999999 | 107.87±15.0585.71±15.0865.10±16.5147.01±16.4534.64±13.2824.18±11.5317.89±9.6212.94±7.249.80±5.867.36±5.144.90±3.88 |
重复测量资料混合效应线性模型 | 组间差异 F=14.80 P=0.0001时间效应 F=1659.70 P<0.0001组间和时间交互作用 F=3.10 P=0.0008 |
用药时间 | 延参组 | 洛非西定组 | 延参组 | 洛非西定组 | ||||
n | 渴 求 | n | 渴 求 | n | 焦 虑 | n | 焦 虑 | |
D0D1D2D3D4D5D6D7D8D9D10 | 297297297297297296295294294294294 | 3.00±0.002.99±0.082.96±0.202.86±0.352.71±0.452.48±0.552.35±0.642.23±0.742.02±0.891.83±0.931.68±0.89 | 9999999999999999999999 | 2.99±0.102.99±0.102.98±0.142.92±0.272.80±0.402.56±0.542.40±0.592.31±0.682.09±0.861.92±0.931.76±0.93 | 297297297297297296295294294294294 | 2.98±0.152.68±0.482.26±0.701.75±0.851.39±0.881.05±0.900.74±0.780.55±0.670.38±0.550.23±0.440.12±0.34 | 9999999999999999999999 | 2.95±0.222.70±0.462.40±0.641.89±0.901.53±0.911.15±0.840.85±0.810.64±0.690.42±0.540.30±0.480.19±0.42 |
重复测量资料混合效应线性模型 | 组间差异 F=2.96 F=0.26 p=0.6100P=0.0861时间效应 F=87.44 F=2159.22 P<0.0001P<0.0001 |
用药时间 | 延参组 | 洛非西定组 | 延参组 | 洛非西定组 | ||||
n | 流泪 | n | 流泪 | n | 骨骼肌肉疼痛 | n | 骨骼肌肉疼痛 | |
D0D1D2D3D4D5D6D7D8 | 297297297297297296295294294 | 5.23±1.223.95±1.552.54±1.601.49±1.450.84±1.160.51±0.950.24±0.690.08±0.430.05±0.31 | 999999999999999999 | 5.23±1.174.24±1.493.11±1.672.00±1.671.17±1.340.55±1.020.20±0.610.08±0.400.06±0.34 | 297297297297297296295294294 | 7.32±2.276.67±2.455.36±2.524.19±2.523.27±2.252.50±2.091.86±1.881.22±1.580.86±1.36 | 999999999999999999 | 7.15±2.346.67±2.375.88±2.344.88±2.374.15±2.213.18±2.142.55±2.031.91±1.741.27±1.55 |
D9D10 | 294294 | 0.03±0.230.01±0.12 | 9999 | 0.04±0.280.00±0.00 | 294294 | 0.62±1.220.31±0.91 | 9999 | 0.94±1.400.52±1.14 |
重复测量资料混合效应线性模型 | 组间差异F=0.31 P=0.5804 F=7.10 P=0.0080时间效应F=755.17 P<0.0001 F=279.47 P<0.0001交互作用 F=2.01 P=0.0317 |
用药时间D0D1D2D3D4D5D6D7D8D9D10 | 延参组 | 洛非西定组 | 延参组 | 洛非西定组 | ||||
n297297297297297296295294294294294 | 腹痛腹泻5.57±2.823.40±2.781.96±2.261.12±1.860.65±1.440.38±1.140.20±0.830.11±0.570.03±0.300.00±0.000.00±0.00 | n9999999999999999999999 | 腹痛腹泻5.45±2.693.73±2.712.12±2.361.48±1.930.82±1.700.30±1.090.15±0.900.06±0.420.03±0.300.00±0.000.00±0.00 | n297297297297297296295294294294294 | 失眠10.36±2.858.89±3.016.91±3.465.41±3.464.30±3.323.51±3.072.74±2.702.23±2.521.73±2.291.29±2.040.83±1.69 | n9999999999999999999999 | 失眠10.18±2.649.17±2.818.24±2.967.43±3.136.59±3.355.49±3.264.77±2.953.88±2.833.56±2.672.91±2.611.82±2.31 | |
重复测量资料混合效应线性模型 | 组间差异F=0.05 P=0.8220 F=33.45 P<0.0001时间效应F=341.47 P<0.0001 F=274.16 P<0.0001交互作用 F=6.01 P<0.0001 |
用药时间 | 延参组 | 洛非西定组 | ||
n | HAMA焦虑量表评分 | n | HAMA焦虑量表评分 | |
D0D5D10 | 297296294 | 29.48±3.829.90±3.362.48±1.47 | 999999 | 29.27±4.1610.83±3.202.97±1.80 |
重复测量资料混合效应线性模型 | 组间差异:F=6.68 P=0.0101时间效应:F=10451.8 P<0.0001 |
疗效 | 延参组(n=311) | 洛非西定组(n=104) | P值(统计量)* |
基本痊愈显著好转好转无效有效率 | 56(18.01%)196(63.02%)52(16.72%)7(2.25%)252(81.03%) | 10(9.62%)61(58.65%)28(26.92%)5(4.81%)71(68.27%) | 0.0009(10.9348)0.0027(8.9736) |
疗效 | 延参组(n=297) | 洛非西定组(n=99) | P值(统计量)* |
基本痊愈显著好转好转无效 | 54(18.18%)191(64.31%)48(16.16%)4(1.35%) | 10(10.10%)58(58.59%)26(26.26%)5(5.05%) | 0.0014(10.2534) |
有效率 | 245(82.49%) | 68(68.69%) | 0.0016(10.0072) |
组别 | 毒瘀热阻证 | 毒瘀寒阻证 | 毒瘀寒热错杂证 | 其它 |
延参组(n=311)洛非西定组(n=104) | 20 | 137 | 29497 | 缺失1例0 |
用药时间 | 延参组 | 洛非西定组 | ||
n | 中医戒断症状总分 | n | 中医戒断症状总分 | |
D0D1D2D3D4D5D6D7D8D9D10 | 297297297297297296295294294294294 | 39.05±5.7931.23±6.7623.06±6.8916.08±6.3411.59±5.078.36±3.906.25±3.204.72±2.503.60±2.122.77±1.742.20±1.42 | 9999999999999999999999 | 38.88±6.2231.97±6.6125.23±7.1818.59±6.8314.16±5.6910.26±4.567.51±3.685.74±2.754.39±2.243.55±2.012.57±1.44 |
重复测量资料混合效应线性模型 | 组间差异 F=11.77 P=0.0007时间效应 F=1119.70 P<0.0001交互作用 F=3.43 P=0.0003 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100174135A CN101229307B (zh) | 2008-01-28 | 2008-01-28 | 一种戒毒口服中药制剂及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100174135A CN101229307B (zh) | 2008-01-28 | 2008-01-28 | 一种戒毒口服中药制剂及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101229307A true CN101229307A (zh) | 2008-07-30 |
CN101229307B CN101229307B (zh) | 2011-01-12 |
Family
ID=39896320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100174135A Active CN101229307B (zh) | 2008-01-28 | 2008-01-28 | 一种戒毒口服中药制剂及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101229307B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105250738A (zh) * | 2015-11-30 | 2016-01-20 | 李嘉 | 一种用于戒毒的药酒 |
CN112402517A (zh) * | 2020-12-12 | 2021-02-26 | 高洪士 | 一种中药戒毒口服液 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100506246C (zh) * | 2006-01-25 | 2009-07-01 | 关志坚 | 一种戒毒中药制剂及其制备方法 |
CN1939515B (zh) * | 2006-10-16 | 2010-05-19 | 童悦 | 戒毒中药制剂及制作方法 |
-
2008
- 2008-01-28 CN CN2008100174135A patent/CN101229307B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105250738A (zh) * | 2015-11-30 | 2016-01-20 | 李嘉 | 一种用于戒毒的药酒 |
CN112402517A (zh) * | 2020-12-12 | 2021-02-26 | 高洪士 | 一种中药戒毒口服液 |
Also Published As
Publication number | Publication date |
---|---|
CN101229307B (zh) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104042909A (zh) | 一种治疗糖尿病的药物 | |
CN105031454A (zh) | 用于治疗肺结核的药物 | |
CN101229307B (zh) | 一种戒毒口服中药制剂及其制备工艺 | |
WO2017152655A1 (zh) | 治疗广泛性焦虑症气血不足证型的中药制剂 | |
CN101011476B (zh) | 一种戒毒中药组合物 | |
CN105497811A (zh) | 一种治疗肝硬化的中药组合物及其制备工艺 | |
CN104784549A (zh) | 用于治疗变应性鼻炎的内服中药 | |
CN104623314A (zh) | 用于治疗口干口苦的药物组合物及其制备方法 | |
CN104474461A (zh) | 一种治疗原发性三叉神经痛的中药制剂及其制备方法 | |
CN105726779A (zh) | 一种用于戒毒的中药组合物及其制备方法 | |
CN106511892A (zh) | 一种戒毒用中药组合物 | |
CN100394976C (zh) | 一种中药戒毒药物 | |
CN102000186A (zh) | 速效戒毒脱瘾纯中药制剂及其制备方法 | |
CN101708230B (zh) | 一种戒毒的药物及其制备方法 | |
CN100506246C (zh) | 一种戒毒中药制剂及其制备方法 | |
CN104840737A (zh) | 具有补气润肺作用的中药组合物及其制备方法和应用 | |
CN105477128A (zh) | 一种具有化湿止带可防治子宫内膜炎的中药组合物 | |
CN101264171A (zh) | 一种用于戒毒的中药组合物及其制备方法和其应用 | |
CN104116912A (zh) | 一种用于肿瘤患者放化疗后康复的中药组合物 | |
CN104721767A (zh) | 一种治疗小儿咳嗽的中药组合物及其制备方法 | |
CN1073432C (zh) | 一种中药戒毒药 | |
CN103520588B (zh) | 一种戒毒用中草药组合物 | |
CN102861289A (zh) | 中药戒毒降三高胶囊 | |
CN108379367A (zh) | 毒品戒断的纯中药药物及其制备方法 | |
CN1513509A (zh) | 终生戒毒脱瘾中草药组合配方 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20081212 Address after: Yangzi Road, Shijiazhuang economic and Technological Development Zone, Hebei Province, China: 052160 Applicant after: Shijiazhuang Yuhui Pharmaceutical Co., Ltd. Address before: Shaanxi province Xianyang City Qin District Century Avenue imperial garden building 7, unit 1, 101 post encoding: 712000 Applicant before: Tian Ye |
|
ASS | Succession or assignment of patent right |
Owner name: SHIJIAZHUANG YUHUI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TIAN YE Effective date: 20081212 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |